Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029412 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
A Phase 2 study of Post-Bariatric Hypoglycemia, sponsored by MBX Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT07029412: Recruiting Phase 2 study of Post-Bariatric Hypoglycemia, sponsored by MBX Biosciences.
NCT07029412 is a Phase 2 study of Post-Bariatric Hypoglycemia that is actively recruiting participants, run by MBX Biosciences. The registered enrollment target is 10 participants, below the 58-participant average among 4 other Post-Bariatric Hypoglycemia trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07029412, a Phase 2 study of Post-Bariatric Hypoglycemia, is actively recruiting participants, sponsored by MBX Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH
Conditions Studied
Interventions
- DRUG MBX 1416 (INN imapextide)
Study Locations (4)
Colorado
- MBX Biosciences Investigational Site - Aurora
North Carolina
- MBX Biosciences Investigational Site - Morehead City
Tennessee
- MBX Biosciences Investigational Site - Knoxville
Texas
- MBX Biosciences Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 2 |
What NCT07029412 shows while recruiting
NCT07029412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 58-participant average among 4 other Post-Bariatric Hypoglycemia trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Post-Bariatric Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which MBX 1416 (INN imapextide) is the first listed.
NCT07029412 reports a single indexed study location in Colorado, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07029412 about?
NCT07029412 is a clinical study titled "Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)". The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH
What is the current status of trial NCT07029412?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-08-26. Estimated completion is 2026-01-26.
What conditions does trial NCT07029412 study?
This clinical trial studies the following conditions: Post-Bariatric Hypoglycemia.
What interventions are being tested in trial NCT07029412?
The interventions under investigation include: MBX 1416 (INN imapextide) (DRUG).
Who is sponsoring clinical trial NCT07029412?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029412 being conducted?
This trial has 4 study locations across Colorado, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-Bariatric Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
ACTIVE NOT RECRUITING · Phase 2
-
Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia
RECRUITING · NA
-
Avexitide for Treatment of Post-Bariatric Hypoglycemia
ACTIVE NOT RECRUITING · Phase 3
-
The Effect of Physical Activity in Individuals With Post-bariatric Hypoglycemia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI